Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Diarrhea associated with afatinib: an oral ErbB family blocker.

Yang JC, Reguart N, Barinoff J, Köhler J, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Wolf J, Cohen EE.

Expert Rev Anticancer Ther. 2013 Jun;13(6):729-36. doi: 10.1586/era.13.31. Epub 2013 Mar 18. Review.

PMID:
23506556
2.

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.

Lacouture ME, Schadendorf D, Chu CY, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Hauschild A.

Expert Rev Anticancer Ther. 2013 Jun;13(6):721-8. doi: 10.1586/era.13.30. Epub 2013 Mar 18. Review.

PMID:
23506519
3.

[A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].

Wislez M, Malka D, Bennouna J, Mortier L, Bensadoun RJ, Sicard J, Dielenseger P, Rey JB, Moro-Sibilot D, Scotté F.

Bull Cancer. 2014 Jun;101(6):647-52. doi: 10.1684/bdc.2014.1986. French.

PMID:
24977454
4.

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.

Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R, Solca F, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J, Spicer J.

Eur J Cancer. 2015 Nov;51(16):2275-84. doi: 10.1016/j.ejca.2015.07.041. Epub 2015 Aug 18.

PMID:
26296295
5.

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F.

Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16.

6.

Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.

Subramaniam D, He AR, Hwang J, Deeken J, Pishvaian M, Hartley ML, Marshall JL.

Curr Cancer Drug Targets. 2015;14(9):775-93. Review.

PMID:
25435079
7.

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.

De Grève J, Moran T, Graas MP, Galdermans D, Vuylsteke P, Canon JL, Schallier D, Decoster L, Teugels E, Massey D, Chand VK, Vansteenkiste J.

Lung Cancer. 2015 Apr;88(1):63-9. doi: 10.1016/j.lungcan.2015.01.013. Epub 2015 Jan 23.

PMID:
25682316
8.

Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.

Hirsh V, Blais N, Burkes R, Verma S, Croitoru K.

Curr Oncol. 2014 Dec;21(6):329-36. doi: 10.3747/co.21.2241.

9.

Afatinib: first global approval.

Dungo RT, Keating GM.

Drugs. 2013 Sep;73(13):1503-15. doi: 10.1007/s40265-013-0111-6. Review.

PMID:
23982599
10.

Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.

Keating GM.

Drugs. 2014 Feb;74(2):207-21. doi: 10.1007/s40265-013-0170-8. Review.

PMID:
24435321
11.

Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.

Kwak EL, Shapiro GI, Cohen SM, Becerra CR, Lenz HJ, Cheng WF, Su WC, Robohn M, Le Maulf F, Lobmeyer MT, Chand VK, Iafrate AJ.

Cancer. 2013 Aug 15;119(16):3043-51. doi: 10.1002/cncr.28120. Epub 2013 Jun 14.

12.

Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.

Spicer J, Baird R, Suder A, Cresti N, Corbacho JG, Hogarth L, Frenkel E, Matsumoto S, Kawabata I, Donaldson K, Posner J, Sarker D, Jodrell D, Plummer R.

Eur J Cancer. 2015 Jan;51(2):137-45. doi: 10.1016/j.ejca.2014.11.003. Epub 2014 Nov 27.

PMID:
25434923
13.

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.

Modjtahedi H, Cho BC, Michel MC, Solca F.

Naunyn Schmiedebergs Arch Pharmacol. 2014 Jun;387(6):505-21. doi: 10.1007/s00210-014-0967-3. Epub 2014 Mar 19. Review.

14.

The ErbB/HER family of protein-tyrosine kinases and cancer.

Roskoski R Jr.

Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Review.

PMID:
24269963
15.

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.

Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R.

J Clin Oncol. 2010 Sep 1;28(25):3965-72. doi: 10.1200/JCO.2009.26.7278. Epub 2010 Aug 2.

PMID:
20679611
16.

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).

Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, Shahidi M, Yamamoto N.

Cancer Chemother Pharmacol. 2012 Apr;69(4):891-9. doi: 10.1007/s00280-011-1738-1. Epub 2011 Nov 10.

PMID:
22071596
17.

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors.

Freiwald M, Schmid U, Fleury A, Wind S, Stopfer P, Staab A.

Cancer Chemother Pharmacol. 2014 Apr;73(4):759-70. doi: 10.1007/s00280-014-2403-2. Epub 2014 Feb 13.

PMID:
24522402
18.

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T.

Breast Cancer Res Treat. 2012 Jun;133(3):1057-65. doi: 10.1007/s10549-012-2003-y. Epub 2012 Mar 15.

19.

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.

Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR.

J Pharmacol Exp Ther. 2012 Nov;343(2):342-50. doi: 10.1124/jpet.112.197756. Epub 2012 Aug 10.

20.

Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.

Engle JA, Kolesar JM.

Am J Health Syst Pharm. 2014 Nov 15;71(22):1933-8. doi: 10.2146/ajhp130654. Review.

PMID:
25349236

Supplemental Content

Support Center